You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Goa coronavirus update: State to start administering remdesivir to patients

Goa's Health Ministry received 1,008 vials of Remdesivir from pharma major Cipla

Coronavirus | Goa | Cipla

IANS  |  Panaji 

coronavirus drug, pharma

Goa's Health Ministry on Friday received 1,008 vials of Remdesivir from pharma major Remdesivir is an anti-viral drug which is administered to Covid-19 patients and results in faster recovery, state Health Minister Vishwajit Rane said.

"This anti-viral drug will be beneficial in suppressing the viral replication of SARS-CoV-2, the that causes COVID-19. Uncontrollable viral replication is often responsible for tissue damage and deaths in patients infected with the virus," Rane said in a statement.

The minister also said that the anti-viral drug will be administered to moderately and severely-ill patients suffering from COVID-19 and would help to suppress the viral replication of SARS-CoV-2.

"The drug will help in faster recovery of COVID-19 patients. Introduction of Remdesivir in the COVID-19 treatment protocol will also help us reduce COVID-19 deaths associated with co-morbidity," Rane said.

is currently witnessing a sustained spike in the number of Covid-19 cases. The state has recorded 7,614 cases in all, out of which 2,095 are active. 66 people have died after contracting the deadly infection.



(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, August 07 2020. 14:07 IST